Tebubio

Executive Summary

Tebubio is a Paris-based contract research organization (CRO) specializing in diagnostics and antibody development. Founded in 2013, the company operates at the pre-clinical stage, offering researchers integrated, platform-based solutions to accelerate drug discovery and diagnostic development. Tebubio’s value proposition centers on its complementary platforms—spanning antibody generation, protein engineering, and assay development—supported by dedicated PhD-level project managers who serve as single points of contact. This model aims to streamline complex workflows, reduce timelines, and ensure high-quality, reproducible results for academic and industry clients. By combining technical expertise with a client-centric approach, Tebubio positions itself as a partner for biotech and pharmaceutical companies seeking to de-risk and expedite their early-stage R&D. The company operates in the rapidly growing CRO market, particularly within the European life sciences ecosystem, and competes by offering flexible, boutique-style services alongside proprietary platform technologies. While Tebubio is privately held and does not disclose financials, its focus on high-value pre-clinical services and its location in a key biotech hub support a positive growth outlook. However, the competitive landscape and limited public information temper conviction.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation antibody discovery platform70% success
• TBDStrategic partnership with a top-20 pharma company for diagnostic assay development50% success
• Q4 2026Expansion into U.S. market via new laboratory facility40% success